Chronic Myeloid Leukemia
Specialty Channel

Featured Article
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of potatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug…
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns…
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?

News

Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.

Interactive Features

Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug…
Stay in the know.
OncNet Newsletter